tradingkey.logo
tradingkey.logo
Suchen

Eton Pharmaceuticals Inc

ETON
Zur Watchlist hinzufügen
37.500USD
+0.870+2.38%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
1.03BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Eton Pharmaceuticals Inc Unternehmen

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc Informationen

BörsenkürzelETON
Name des UnternehmensEton Pharmaceuticals Inc
IPO-datumNov 09, 2018
CEOBrynjelsen (Sean E)
Anzahl der mitarbeiter31
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse21925 W Field Pkwy Ste 235
StadtDEER PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl60010-7278
Telefon18477877361
Websitehttps://etonpharma.com/
BörsenkürzelETON
IPO-datumNov 09, 2018
CEOBrynjelsen (Sean E)

Führungskräfte von Eton Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Eton Pharmaceuticals Inc?

Die fünf größten Anteilseigner von Eton Pharmaceuticals Inc sind: Mr. Sean E. Brynjelsen

Wie viele Institutionen halten Anteile an Eton Pharmaceuticals Inc (ETON)?

Mit Stand vom 2026Q1 halten 235 Institutionen Anteile an Eton Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 15.99M, was 58.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3678435.00 gestiegen.